Drug interactions
Ublituximab + Valganciclovir
Severity: Moderate
Ublituximab and Valganciclovir: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ublituximab depletes B cells and raises susceptibility to infections, including viral reactivation. Valganciclovir is not made less potent, but myelosuppression from valganciclovir may add to cytopenias seen with anti-CD20 therapy.
What this interaction means in plain words
Ublituximab and Valganciclovir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ublituximab belongs to Miscellaneous; Valganciclovir belongs to Anti Virals.
Why it happens
Additive pharmacodynamic effects of immunosuppression and possible overlapping neutropenia; no pharmacokinetic interaction.
What to do
Monitor complete blood counts and for signs of infection during concurrent therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ublituximab and Valganciclovir, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Valganciclovir
Other interactions of Ublituximab
Frequently asked questions
Can I take Ublituximab with Valganciclovir?
MediHelp rates the interaction as moderate. Ublituximab and Valganciclovir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ublituximab depletes B cells and raises susceptibility to infections, including viral reactivation. Valganciclovir is not made less potent, but myelosuppression from valganciclovir may add to cytopenias seen with anti-CD20 therapy.
How serious is the interaction between Ublituximab and Valganciclovir?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor complete blood counts and for signs of infection during concurrent therapy.
What other medicines interact with Valganciclovir?
MediHelp also lists interactions of Valganciclovir with, for example, Didanosine, Ganciclovir, Liposomal doxorubicin. The full list is on the Valganciclovir page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
